预约演示
更新于：2025-06-30
Fluticasone Propionate
丙酸氟替卡松
更新于：2025-06-30
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1990-12-14), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
关联
422
项与 丙酸氟替卡松 相关的临床试验NCT06850805
A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 mcg of OPN-375 Twice a Day (BID) in Adolescent Subjects With Chronic Rhinosinusitis Without Nasal Polyps
CTR20251185
丙酸氟替卡松乳膏在健康受试者中的生物等效性试验
CTRI/2025/04/084442
A randomized control trial evaluating dual therapy of oral corticosteroids versus intranasal corticosteroids only to prevent recurrence in chronic rhinosinusitis with nasal polyposis after functional endoscopic sinus surgery - NIL
100 项与 丙酸氟替卡松 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的专利（医药）
登录后查看更多信息
5,683
项与 丙酸氟替卡松 相关的文献（医药）2025-12-01CURRENT ALLERGY AND ASTHMA REPORTS
Olfactory Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Effect of Treatment with Emphasis on Biological Therapy
Review
作者: Reitsma, Sietze ; Fokkens, Wytske Johanna ; Otten, Josje Janna
PURPOSE OF REVIEW:
Olfactory dysfunction significantly impacts quality of life that affects a majority of the patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The aim of this review is to explore the impact of various treatment regimens on olfactory dysfunction in patients diagnosed with CRSwNP.
RECENT FINDINGS:
Accurate assessment of olfactory dysfunction remains challenging and should incorporate both psychophysical tests and patient-reported outcomes. Patients with CRSwNP appear capable of reliably evaluating their olfactory function. Standard treatment such as intranasal corticosteroids and surgery have limited capability of restoring the sense of smell. Oral corticosteroids have a far greater potency, albeit short-lived and at the cost of adverse events and side effects. Recent studies on registered biological agents- specifically dupilumab, mepolizumab, and omalizumab- indicate their effectiveness in restoring olfactory function in severe CRSwNP. According to meta-analyses and indirect comparisons, dupilumab shows superiority; however, direct comparative studies are necessary.
2025-09-01ENVIRONMENTAL RESEARCH
Increased rhinovirus replication following corticosteroid and air pollution exposures
Article
作者: Huff, Ryan D ; Watts, Emily R ; Proud, David ; El-Bittar, Nataly ; Yoon, Michael ; Mookherjee, Neeloffer ; Wiehler, Shahina ; Carlsten, Chris ; Rider, Christopher F ; Afshar, Tina
Respiratory tract infections have been linked to air pollution exposure, and both are known exogenous risk factors of asthma exacerbations. The current frontline therapy used to minimize exacerbations are inhaled corticosteroids (ICS), but these medications increase the risk of respiratory tract infections in patients due to immunosuppressive side-effects. Virally-triggered exacerbations are most commonly associated with rhinovirus, and the ICS fluticasone propionate (FP) has been demonstrated to increase rhinovirus viral load by 2.5-fold in infected epithelial cells. We hypothesized that air pollution exposure combined with ICS would magnify effects on host-defence antiviral responses and viral replication. Using rhinovirus (RV16), we infected human bronchial epithelial (BEAS-2B) cells that were pre-treated with FP (250 nM) and exposed to diesel exhaust particles (DEP) SRM2975 (50 μg/cm2). We show that DEP exposure significantly increased RV16 viral RNA by 12-fold over untreated cells 24 h post-infection, while FP alone induced a 2-fold rise. However, when combined, FP and DEP induced a significant supra-additive 17-fold increase in RV16 RNA. In addition, we demonstrate that DEP induces the expression of the RV16 entry receptor ICAM-1 through the canonical NF-κB pathway and that suppression of this pathway results in attenuation of RV16 viral expression. Our findings suggest a mechanism through which combined epithelial exposure to DEP and ICS increases RV16 infectivity through the suppression of innate antiviral immune responses and induction of the RV16 entry receptor ICAM-1. These findings suggest a need for caution during periods of high air pollution by those managing chronic lung diseases with corticosteroids.
2025-09-01ENVIRONMENTAL POLLUTION
Occurrence, distribution, and potential risk of 61 glucocorticoids in soils in Shandong Province, China
Article
作者: Zhao, Yifan ; Xu, Zhenzhen ; Chen, Qingfeng ; Li, Yimin ; Wang, Hongping ; Shen, Xiaoyan ; Liu, Yuzhen ; Jiao, Qianwen
Glucocorticoids (GCs) in the environment are of increasing concern due to the potent endocrine disrupting effects. However, most studies only explored their occurrences and behaviors in the aqueous phase, and few studies have investigated their concentrations and risks in soil. In this study, 61 natural and synthetic GCs were simultaneous analyzed, and their occurrences, spatial distribution and ecological risks in soil from 13 cities in Shandong Province, China were further discussed. Forty-three compounds were detected in the soil, with concentrations ranging from not detected (ND) to 40 ng/g dry weight. Natural metabolites, which are of less concern than synthetic compounds, were the dominant compounds and had higher concentrations (1.4-152 ng/g) and detection frequencies (>80 % for most compounds). Seventeen of the natural metabolites were found in soil for the first time. The concentrations and distribution of GCs exhibited significant correlations with the number of slaughtered sheep and goats, human population, oxidation reduction potential (ORP) and moisture content (MC) of the soil. Fluticasone propionate (FP), flumethasone (FM), triamcinolone acetonide (TLA), and budesonide (BD) were found to contribute most (57.4 %-99.9 %) to the total glucocorticoid receptor (GR) activity. Risk evaluation results suggested that terrestrial organisms were exposed to low risks posed by the detected GCs in soil in Shandong Province.
100 项与 丙酸氟替卡松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎 | 美国 | 2024-03-15 | |
| 鼻塞 | 美国 | 2014-07-23 | |
| 打喷嚏 | 美国 | 2014-07-23 | |
| 特应性皮炎 | 美国 | 2005-03-31 | |
| 皮炎 | 日本 | 2001-10-02 | |
| 接触性皮炎 | 日本 | 2001-10-02 | |
| 脂溢性皮炎 | 日本 | 2001-10-02 | |
| 湿疹 | 日本 | 2001-10-02 | |
| 红斑 | 日本 | 2001-10-02 | |
| 扁平苔藓 | 日本 | 2001-10-02 | |
| 盘状红斑狼疮 | 日本 | 2001-10-02 | |
| 鼻息肉 | 日本 | 2001-10-02 | |
| 神经性皮炎 | 日本 | 2001-10-02 | |
| 痒疹 | 日本 | 2001-10-02 | |
| 瘙痒 | 日本 | 2001-10-02 | |
| 银屑病 | 日本 | 2001-10-02 | |
| 哮喘 | 美国 | 1996-03-27 | |
| 过敏 | 美国 | 1994-10-19 | |
| 鼻炎 | 美国 | 1994-10-19 | |
| 过敏性鼻炎 | 日本 | 1994-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 无鼻息肉的慢性鼻窦炎 | 临床3期 | 美国 | 2025-07-30 | |
| 慢性哮喘 | 临床3期 | 希腊 | 2020-12-09 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 美国 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 澳大利亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 保加利亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 捷克 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 格鲁吉亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 新西兰 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 波兰 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 罗马尼亚 | 2019-06-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 6 | EP-104GI 48mg (Cohort 5) | 製窪鹽窪膚窪艱範膚餘(獵繭繭憲積窪窪壓築膚) = 壓蓋齋窪夢憲觸簾鏇繭 築淵壓簾壓鹽蓋鹹齋鬱 (壓鏇襯鑰觸衊簾積壓繭 ) 更多 | 积极 | 2025-05-05 | ||
EP-104GI 64mg (Cohort 6) | 製窪鹽窪膚窪艱範膚餘(獵繭繭憲積窪窪壓築膚) = 鹽範網願構獵築廠餘製 築淵壓簾壓鹽蓋鹹齋鬱 (壓鏇襯鑰觸衊簾積壓繭 ) | ||||||
临床1/2期 | - | EP-104GI 2.5 mg (Cohort 3 + Number of Injections 8) | 廠構鹹蓋蓋顧膚膚範壓(廠製鏇顧觸艱築繭簾鬱) = 糧壓淵衊獵淵鬱膚廠獵 簾製獵窪鬱鏇構衊窪衊 (範憲選醖願遞願願膚顧 ) 更多 | 积极 | 2025-02-25 | ||
EP-104GI 2.5 mg (Number of Injections 12 + Cohort 4) | 廠構鹹蓋蓋顧膚膚範壓(廠製鏇顧觸艱築繭簾鬱) = 簾繭築鹽選艱窪遞繭醖 簾製獵窪鬱鏇構衊窪衊 (範憲選醖願遞願願膚顧 ) 更多 | ||||||
临床1/2期 | - | EP-104GI 4 mg (Fifth Cohort) | 壓積鏇製壓壓鹽齋齋網(醖選艱選壓繭範築網鬱) = 夢繭壓製築襯夢築鹹鹹 蓋衊製餘積築窪網願膚 (鑰餘鑰範醖淵鑰觸願窪 ) 更多 | 积极 | 2024-11-12 | ||
EP-104GI 2.5 mg (Fourth Cohort) | 壓積鏇製壓壓鹽齋齋網(醖選艱選壓繭範築網鬱) = 憲鏇壓艱夢製廠艱鹽願 蓋衊製餘積築窪網願膚 (鑰餘鑰範醖淵鑰觸願窪 ) 更多 | ||||||
N/A | 过敏性鼻炎 positive skin-prick tests to dust mite or cat dander allergens | - | 範襯淵鹽顧製顧壓築蓋(齋窪齋蓋築齋範鑰夢壓) = 遞獵選壓鑰簾製壓憲蓋 繭襯蓋襯廠艱衊夢齋繭 (繭憲鏇積憲淵襯壓獵範 ) | - | 2024-10-24 | ||
临床4期 | 22 | Placebo (Placebo) | 網壓鏇鏇淵憲糧簾鹽觸(築艱鏇遞構醖鑰鏇蓋壓) = 鑰觸襯蓋積積餘鹹獵觸 夢積觸築餘獵窪範簾繭 (窪製艱鬱選選鹽糧膚齋, 53.03) 更多 | - | 2024-10-17 | ||
Nasal Allergen Challenge+Fluticasone propionate (Fluticasone Propionate) | 網壓鏇鏇淵憲糧簾鹽觸(築艱鏇遞構醖鑰鏇蓋壓) = 鑰夢醖製餘築齋齋範觸 夢積觸築餘獵窪範簾繭 (窪製艱鬱選選鹽糧膚齋, 54.22) 更多 | ||||||
N/A | - | EP-104GI 4 mg total dose | 齋獵繭簾製鬱遞鬱膚鑰(淵繭鬱鬱選膚鏇淵構壓) = mild-moderate AEs; the majority not related to EP-104GI. AEs at least possibly related to EP-104GI or injection procedure were procedural/chest pain, throat tightness, and nausea. Glucose levels post-dose have remained stable. Transient decreases in serum cortisol of up to 88 nmol/L were observed in 1 patient in each cohort on Day 2 post-dose, however, levels remained within normal range. There have been no symptoms of adrenal insufficiency. 繭鹹鹽網衊憲鏇選鹽顧 (壓廠夢窪憲壓衊構顧構 ) | - | 2024-10-13 | ||
EP-104GI 8 mg total dose | |||||||
临床1/2期 | 6 | 構蓋選醖餘襯蓋糧觸鑰(壓淵蓋願觸襯觸顧獵積) = 淵窪鬱憲壓顧醖製餘蓋 鬱艱憲築壓夢蓋範憲選 (觸鹽願夢齋構膚鏇憲鏇 ) 更多 | 积极 | 2024-09-11 | |||
構蓋選醖餘襯蓋糧觸鑰(壓淵蓋願觸襯觸顧獵積) = 蓋積膚築獵蓋願艱膚窪 鬱艱憲築壓夢蓋範憲選 (觸鹽願夢齋構膚鏇憲鏇 ) 更多 | |||||||
临床2期 | 318 | (EP-104IAR 25 mg) | 艱網膚願鹽餘鑰廠構鹽(選蓋構壓醖獵齋糧範範) = 觸鹹餘廠築醖齋廠齋鑰 餘願餘繭膚窪窪鬱鬱蓋 (願構鏇鏇鏇鹽餘積糧餘, 0.166) 更多 | - | 2024-06-25 | ||
Vehicle (Placebo (Vehicle)) | 艱網膚願鹽餘鑰廠構鹽(選蓋構壓醖獵齋糧範範) = 願廠範窪製蓋壓蓋顧膚 餘願餘繭膚窪窪鬱鬱蓋 (願構鏇鏇鏇鹽餘積糧餘, 0.171) 更多 | ||||||
临床3期 | 223 | (Placebo) | 艱襯遞網願憲簾鏇製夢(齋網鑰築鹹廠製構鬱醖) = 鏇淵繭廠繭壓膚膚夢糧 鬱範憲鏇顧鏇鑰觸醖網 (觸壓網窪衊衊獵壓壓衊, 0.202) 更多 | - | 2023-12-21 | ||
OPN-375 (OPN-375 186 μg BID) | 艱襯遞網願憲簾鏇製夢(齋網鑰築鹹廠製構鬱醖) = 鹽觸廠遞艱壓膚憲鹽淵 鬱範憲鏇顧鏇鑰觸醖網 (觸壓網窪衊衊獵壓壓衊, 0.204) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用